Drug intelligence / Profile preview

FucoBalan

Development stage: Unknown
Lead developer: Hi-Q Marine Biotech International
Modality: Small Molecules
Administration: Oral

Overview

FucoBalan is a branded functional ingredient developed by Hi-Q Marine Biotech International, combining low molecular weight Oligo Fucoidan (500-1500 Da) and high-stability fucoxanthin extracted from brown seaweed (*Laminaria japonica*). It is designed to support metabolic health, specifically targeting blood glucose regulation, liver function, and lipid metabolism. Clinical studies have demonstrated its potential in reducing HbA1C, liver steatosis, and alanine aminotransferase (ALT) levels in patients with non-alcoholic fatty liver disease (NAFLD). It is primarily used as a bioactive component in dietary supplements like BalanGluco.

Brand names: FucoBalanBalanGluco
Other names: Oligo Fucoidan + Fucoxanthin

Beyond the preview

Go deeper on FucoBalan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FucoBalan.

Explore the full profile